Cerevel Therapeutics Holdings, Inc.
NASDAQ Capital MarketTotal Valuation
Cerevel Therapeutics Holdings, Inc. carries a market capitalization of 8.19B, placing it among publicly traded companies globally. Its enterprise value stands at 6.51B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 8.19B |
| Enterprise Value | 6.51B |
Share Statistics
Cerevel Therapeutics Holdings, Inc. currently has 181.89M shares outstanding.
| Shares Outstanding | 181.89M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -4.56 |
| P/TBV Ratio | 12.39 |
| P/FCF Ratio | -19.24 |
| P/OCF Ratio | -19.05 |
Financial Position
Cerevel Therapeutics Holdings, Inc. maintains a current ratio of 10.22, meaning it holds 10.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 65.25, indicating elevated leverage, while an interest coverage ratio of -45.78 demonstrates limited ability to service its debt obligations.
| Current Ratio | 10.22 |
| Quick Ratio | 10.12 |
| Debt / Equity | 65.25 |
| Debt / EBITDA | -0.76 |
| Interest Coverage | -45.78 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -44.76 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 556,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Cerevel Therapeutics Holdings, Inc.'s stock has gained approximately 87.88132% over the past 52 weeks. The 50-day moving average sits at 41.60, while the 200-day moving average is 38.67.
| Beta (5Y) | N/A |
| 52-Week Price Change | 87.88132% |
| 50-Day Moving Average | 41.60 |
| 200-Day Moving Average | 38.67 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -484.52M, while operating income came in at -490.37M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -490.37M |
| Pretax Income | -459.91M |
| Net Income | -460.47M |
| EBITDA | -484.52M |
| EBIT | -490.37M |
| Earnings Per Share (EPS) | -2.78 |
Balance Sheet
Cerevel Therapeutics Holdings, Inc. holds 846.29M in cash and equivalents against 368.30M in total debt, resulting in a net debt position of 17.48M. Total book value stands at -1.53B, with working capital of 775.47M providing operational flexibility.
| Cash & Cash Equivalents | 846.29M |
| Total Debt | 368.30M |
| Net Debt | 17.48M |
| Equity (Book Value) | -1.53B |
| Book Value Per Share | -9.27 |
| Working Capital | 775.47M |
Cash Flow
Cerevel Therapeutics Holdings, Inc. produced -367.05M in operating cash flow over the past twelve months. After subtracting -3.74M in capital expenditures, free cash flow totaled -370.79M - equivalent to -2.24 per share.
| Operating Cash Flow | -367.05M |
| Capital Expenditures | -3.74M |
| Free Cash Flow | -370.79M |
| FCF Per Share | -2.24 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -7.89 |
| FCF Yield | -5.20 |
Scores
Cerevel Therapeutics Holdings, Inc. posts an Altman Z-Score of 4.94, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.94 |